RNA Targeting Small Molecule Drug Discovery Market Size, Share & Trends Report

RNA Targeting Small Molecule Drug Discovery Market Size, Share & Trends Analysis Report By Indication, By End-user, By Region, And Segment Forecasts, 2022 To 2030

Report ID: GVR453383
Number of Pages: 0
Format: Electronic (PDF)

Historical Data: ---
Industry: Healthcare

Table of Contents

Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.1.1. Indication
1.1.2. End User
1.1.3. Regional scope
1.1.4. Estimates and forecast timeline
1.2. Research Methodology
1.3. Information Procurement
1.3.1. Purchased database
1.3.2. GVR’s internal database
1.3.3. Secondary sources
1.3.4. Primary research
1.4. Information or Data Analysis
1.4.1. Data analysis models
1.5. Market Formulation & Validation
1.6. Model Details
1.6.1. Commodity flow analysis (Model 1)
1.6.2. Volume price analysis (Model 2)
1.7. List of Secondary Sources
1.8. List of Primary Sources
1.9. Objectives
1.9.1. Objective 1
1.9.2. Objective 2
1.9.3. Objective 3
1.9.4. Objective 4
Chapter 2. Executive Summary
2.1. Market Outlook
Chapter 3. RNA Targeting Small Molecule Drug Discovery Market Variables, Trends & Scope
3.1. Market Lineage Outlook
3.1.1. Parent market outlook
3.1.2. Related/ancillary market outlook
3.2. Penetration & Growth Prospect Mapping
3.3. Market Dynamics
3.3.1. Market driver analysis
3.3.2. Market restraint analysis
3.3.3. Penetration & Growth Prospect Mapping
3.3.4. Covid-19 Impact & Recovery Analysis
3.3.5. Major Deals and Strategic Alliances Analysis
3.3.6. Industry Analysis - Porter’s
3.3.7. PESTLE Analysis
Chapter 4. RNA Targeting Small Molecule Drug Discovery Market: Indication Segment Analysis
4.1. RNA Targeting Small Molecule Drug Discovery Market : Definition & Scope
4.2. RNA Targeting Small Molecule Drug Discovery Market : Indication Market Share Analysis, 2021 & 2030
4.2.1. Cancer
4.2.1.1. Cancer Market, 2018 - 2030 (USD Million)
4.2.2. Infectious Diseases
4.2.2.1. Infectious Diseases Market, 2018 - 2030 (USD Million)
4.2.3. Metabolic Diseases
4.2.3.1. Metabolic Disease Market, 2018 - 2030 (USD Million)
4.2.4. Neurological Diseases
4.2.4.1. Neurological Disease Market, 2018 - 2030 (USD Million)
4.2.5. Others
4.2.5.1. Others Market, 2018 - 2030 (USD Million)
Chapter 5. RNA Targeting Small Molecule Drug Discovery Market : End User Segment Analysis
5.1. RNA Targeting Small Molecule Drug Discovery Market :Definition & Scope
5.2. RNA Targeting Small Molecule Drug Discovery Market : End-User Market Share Analysis, 2021 & 2030
5.2.1. Pharmaceutical and Biopharmaceutical Comapnies
5.2.1.1. Synthetic Market, 2018 - 2030 (USD Million)
5.2.2. Accademic and Research Institutes
5.2.2.1. Academic and Research Institutes Market, 2018 - 2030 (USD Million)
5.2.3. Others
5.2.3.1. Others Market, 2018 - 2030 (USD Million)
Chapter 6. RNA Targeting Small Molecule Drug Discovery Market: Regional Analysis
6.1. Healthcare Finance Solutions: Regional market share analysis, 2021 & 2030
6.2. North America
6.2.1. North America Market estimates and forecast, 2018 - 2030
6.2.2. U.S.
6.2.2.1. U.S. Market estimates and forecast, 2018 - 2030
6.2.3. Canada
6.2.3.1. Canada Market estimates and forecast, 2018 - 2030
6.3. Europe
6.3.1. Europe Market estimates and forecast, 2018 - 2030
6.3.2. UK
6.3.2.1. UK Market estimates and forecast, 2018 - 2030
6.3.3. Germany
6.3.3.1. Germany Market estimates and forecast, 2018 - 2030
6.3.4. France
6.3.4.1. France Market estimates and forecast, 2018 - 2030
6.3.5. Italy
6.3.5.1. Italy Market estimates and forecast, 2018 - 2030
6.3.6. Spain
6.3.6.1. Spain Market estimates and forecast, 2018 - 2030
6.3.7. Russia
6.3.7.1. Russia Market estimates and forecast, 2018 - 2030
6.3.8. Turkey
6.3.8.1. Turkey Market estimates and forecast, 2018 - 2030
6.3.9. Netherlands
6.3.9.1. Netherlands Market estimates and forecast, 2018 - 2030
6.3.10. Switzerland
6.3.10.1. Switzerland Market estimates and forecast, 2018 - 2030
6.3.11. Sweden
6.3.11.1. Sweden Market estimates and forecast, 2018 - 2030
6.4. Asia Pacific
6.4.1. Asia Pacific Market estimates and forecast, 2018 - 2030
6.4.2. Japan
6.4.2.1. Japan Market estimates and forecast, 2018 - 2030
6.4.3. China
6.4.3.1. China Market estimates and forecast, 2018 - 2030
6.4.4. India
6.4.4.1. India Market estimates and forecast, 2018 - 2030
6.4.5. Thailand
6.4.5.1. Thailand Market estimates and forecast, 2018 - 2030
6.4.6. South Korea
6.4.6.1. South Korea Market estimates and forecast, 2018 - 2030
6.4.7. Indonesia
6.4.7.1. Indonesia Market estimates and forecast, 2018 - 2030
6.4.8. Malaysia
6.4.8.1. Malaysia Market estimates and forecast, 2018 - 2030
6.4.9. Singapore
6.4.9.1. Singapore Market estimates and forecast, 2018 - 2030
6.4.10. Thailand
6.4.10.1. Thailand Market estimates and forecast, 2018 - 2030
6.4.11. Taiwan
6.4.11.1. Taiwan Market estimates and forecast, 2018 - 2030
6.5. Latin America
6.5.1. Latin America Market estimates and forecast, 2018 - 2030
6.5.2. Brazil
6.5.2.1. Brazil Market estimates and forecast, 2018 - 2030
6.5.3. Mexico
6.5.3.1. Mexico Market estimates and forecast, 2018 - 2030
6.5.4. Argentina
6.5.4.1. Argentina Market estimates and forecast, 2018 - 2030
6.5.5. Colombia
6.5.5.1. Colombia Market estimates and forecast, 2018 - 2030
6.5.6. Chile
6.5.6.1. Chile Market estimates and forecast, 2018 - 2030
6.6. MEA
6.6.1. MEA Market estimates and forecast, 2018 - 2030
6.6.2. South Africa
6.6.2.1. South Africa Market estimates and forecast, 2018 - 2030
6.6.3. Saudi Arabia
6.6.3.1. Saudi Arabia Market estimates and forecast, 2018 - 2030
6.6.4. UAE
6.6.4.1. UAE Market estimates and forecast, 2018 - 2030
6.6.5. Egypt
6.6.5.1. Egypt Market estimates and forecast, 2018 - 2030
6.6.6. Israel
6.6.6.1. Israel Market estimates and forecast, 2018 - 2030
Chapter 7. Competitive Landscape
7.1. Company Profiles
7.1.1. Nymirum
7.1.1.1. Company overview
7.1.1.2. Financial performance
7.1.1.3. Service benchmarking
7.1.1.4. Strategic initiatives
7.1.2. Remix Therapeutics
7.1.2.1. Company overview
7.1.2.2. Financial performance
7.1.2.3. Service benchmarking
7.1.2.4. Strategic initiatives
7.1.3. Evotec
7.1.3.1. Company overview
7.1.3.2. Financial performance
7.1.3.3. Service benchmarking
7.1.3.4. Strategic initiatives
7.1.4. AXXAM S.p.A.
7.1.4.1. Company overview
7.1.4.2. Financial performance
7.1.4.3. Service benchmarking
7.1.4.4. Strategic initiatives
7.1.5. Arrakis Therapeutics
7.1.5.1. Company overview
7.1.5.2. Financial performance
7.1.5.3. Service benchmarking
7.1.5.4. Strategic initiatives
7.1.6. Ribometrix
7.1.6.1. Company overview
7.1.6.2. Financial performance
7.1.6.3. Service benchmarking
7.1.6.4. Strategic initiatives
7.1.7. Santaris A/S
7.1.7.1. Company overview
7.1.7.2. Financial performance
7.1.7.3. Service benchmarking
7.1.7.4. Strategic initiatives
7.1.8. xFOREST Therapeutics Co., Ltd
7.1.8.1. Company overview
7.1.8.2. Financial performance
7.1.8.3. Service benchmarking
7.1.8.4. Strategic initiatives
7.1.9. Veritas In Silico Inc.
7.1.9.1. Company overview
7.1.9.2. Financial performance
7.1.9.3. Service benchmarking
7.1.9.4. Strategic initiatives
7.1.10. HitGen Inc.
7.1.10.1. Company overview
7.1.10.2. Financial performance
7.1.10.3. Service benchmarking
7.1.10.4. Strategic initiatives

GET A FREE SAMPLE

This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.

Or view our licence options:

NEED A CUSTOM REPORT?

We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities.

ESOMAR certified & member

Leading SME award by D&B

We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure. For more details, please read our privacy policy.